Cardiovascular effects of iodinated contrast agents.

The ideal intravascular contrast agent would be biologically inert and have no pharmacologic actions. Pharmacologic actions of currently used radiographic contrast agents are determined principally by 3 physicochemical properties of the iodine-bearing molecule and its formulation: osmolality, sodium concentration and calcium-binding properties. Within this framework, the calcium-binding 1.5 ratio agents have the most marked effects, and the 3.0 ratio nonionic agents the least, with the noncalcium-binding formulations of 1.5 ratio agents and ioxaglate (the only 3.0 ratio ionic agent) in between. Differences in hemodynamic effects are predominantly related to osmolality with the 3.0 agents causing less hemodynamic disturbance. The magnitude of difference is small enough that the 3.0 ratio agents have no important clinical advantage when used in patients with good or moderately impaired left ventricular function. However, the difference may be important in patients with severely impaired circulatory performance. The principal electrophysiologic differences are between the calcium-binding 1.5 ratio agents (which are associated with a clear-cut greater frequency of ventricular fibrillation during coronary injection than the noncalcium-binding 1.5 ratio agents) and the 3.0 ratio agents. There is no justification for the use of calcium-binding 1.5 ratio agents, since noncalcium-binding formulations of the same molecule are available at the same price. The circulatory reserve of most patients makes the differences between 3.0 ratio agents and noncalcium-binding 1.5 ratio agents clinically unimportant. In view of the substantial price disparity between 1.5 ratio and 3.0 ratio agents, noncalcium-binding 1.5 ratio agents are appropriate for patients with good circulatory performance and 3.0 ratio agents are best reserved for patients with impaired circulatory performance.(ABSTRACT TRUNCATED AT 250 WORDS)